» Articles » PMID: 31932270

HAE-AS: A Specific Disease Activity Scale for Hereditary Angioedema With C1-Inhibitor Deficiency

Overview
Date 2020 Jan 15
PMID 31932270
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objective: The activity of hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) varies between patients and within individual patients. Objective: This study aims to develop a disease activity scale for C1-INH-HAE (HAE-AS) with sound measurement properties.

Methods: Eleven countries participated in a prospective multicenter cohort study. A clinical questionnaire was self-completed by 290 adult patients with C1-INH-HAE. Patients also completed 2 quality of life scales, the SF-36v2 and the HAE-QoL. Rasch analysis and classic psychometric methods were used to preselect a series of clinical items: number of attacks by location and number of treated attacks, emergency room visits, psychological/psychiatric treatment, missed school/workdays in the previous 6 months; general health; and impairment in everyday work/activities due to pain.

Results: The mean (SD) age was 41.5 (14.7; range, 18-84) years, and 69% were females. The final 12-item Rasch model showed that the HAE-AS had satisfactory reliability (person separation index, 0.748), local item independence, unidimensionality, and no item bias by age or sex. The HAE-AS provided scores in a linear measure, with a mean of 10.66 (3.92; range, 0-30). Further analysis with classic psychometric methods indicated that the HAE-AS linear measure presented moderate-to-high convergent validity with quality of life scales (SF-36v2: physical component, r=-0.33; mental component, 0.555; HAE-QoL, -0.61), and good discriminative validity by age, sex, and disease severity (P<.05).

Conclusions: The HAE-AS is a short, valid, reliable, and psychometrically sound measure of the activity of C1-INH-HAE that could prove useful for research studies.

Citing Articles

or inherited: gonosomal mosaicism in hereditary angioedema due to C1 inhibitor deficiency.

Batlle-Maso L, Perurena-Prieto J, Vinas-Gimenez L, Aguilo-Cucurull A, Fernandez-Alvarez P, Gil-Serrano J Front Immunol. 2025; 16:1550380.

PMID: 39981253 PMC: 11839619. DOI: 10.3389/fimmu.2025.1550380.


Hereditary angioedema prevalence and satisfaction with prophylaxis in South Australia.

Troelnikov A, Milburn K, Hissaria P, Thao Adriana Le T, Smith W World Allergy Organ J. 2024; 17(7):100918.

PMID: 39006039 PMC: 11239692. DOI: 10.1016/j.waojou.2024.100918.


Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review.

Guan X, Sheng Y, Liu S, He M, Chen T, Zhi Y Orphanet J Rare Dis. 2024; 19(1):256.

PMID: 38978028 PMC: 11229247. DOI: 10.1186/s13023-024-03265-z.


Myeloid lineage cells evince distinct steady-state level of certain gene groups in dependence on hereditary angioedema severity.

Ballonova L, Soucek P, Slanina P, Reblova K, Zapletal O, Vlkova M Front Genet. 2023; 14:1123914.

PMID: 37470035 PMC: 10352584. DOI: 10.3389/fgene.2023.1123914.


The symptom experience of hereditary angioedema (HAE) patients beyond HAE attacks: literature review and clinician interviews.

Jean-Baptiste M, Itzler R, Prusty S, Supina D, Martin M Orphanet J Rare Dis. 2022; 17(1):232.

PMID: 35710442 PMC: 9204898. DOI: 10.1186/s13023-022-02360-3.